Government https://www.benzinga.com/views/taxonomy/term/26029 en Cannabis In Mexico: Uncertainty Swirls Heading Into June Elections After Lawmakers Fail To Pass Adult-Use Laws Yet Again https://www.benzinga.com/markets/cannabis/21/05/20997601/cannabis-in-mexico-uncertainty-swirls-heading-into-june-elections-after-lawmakers-fail-to-pass-a <p>On April 30, Mexico&#39;s Congress&nbsp;failed to pass adult-use legalization orders that were handed down by five Supreme Court rulings. The latest development marks the fourth time the deadline has not been met.</p> <p>The decision puts the&nbsp;future of cannabis legalization into an&nbsp;uncertain area in Mexico as operators, advocates and lawmakers await the next steps.</p> <h2>Government Stalls Legislation Once Again</h2> <p>In the past, the COVID-19 pandemic and disputes over the bill derailed the various processes.</p> <p>This time around was more of the latter. Blame appears to be centered on changes in the bill between congressional chambers, the Senate and the House of Deputies.</p> <p>A primary sticking point&nbsp;focused on overseeing the licensing and rollout of the cannabis program.</p> <p>Zara Snapp, the co-founder of drug policy group <strong>Instituto RIA</strong>, believes the upcoming June 6 legislative elections also played a part.</p> <p>&quot;Obviously, there&#39;s a concern about how passing this law might affect those outcomes,&quot; Snapp said.</p> <p>With 500 deputy positions up for grabs&nbsp;in the house, most don&#39;t expect much forward movement&nbsp;before the results are determined.</p> <p>Raul Elizalde, president ...</p><p><a href=https://www.benzinga.com/markets/cannabis/21/05/20997601/cannabis-in-mexico-uncertainty-swirls-heading-into-june-elections-after-lawmakers-fail-to-pass-a alt=Cannabis In Mexico: Uncertainty Swirls Heading Into June Elections After Lawmakers Fail To Pass Adult-Use Laws Yet Again>Full story available on Benzinga.com</a></p> Cannabis Government HempMeds Latin America Hoban Law Group Instituto RIA MJNA News Penny Stocks Regulations Markets Interview MJNA US58463A1051 News Penny Stocks Government Cannabis Regulations Markets Interview Benzinga Sat, 08 May 2021 15:46:59 +0000 Andrew Ward 20997601 at https://www.benzinga.com EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots https://www.benzinga.com/general/biotech/21/05/21016760/ema-safety-committee-reviews-heart-inflammation-rare-nerve-disorder-reports-after-pfizer-astrazen <p>European Medical Agency (EMA) is&nbsp;<a class="editor-rtfLink" href="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">reviewing reports</a>&nbsp;of a rare nerve-degenerating disorder in people who received&nbsp;<strong>AstraZeneca Plc&rsquo;s</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/azn#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">AZN</a>) COVID-19 vaccine, raising new questions about potential side effects of the shot.</p> <p><strong>What Happened:</strong>&nbsp;As part of a regular review of safety reports for the vaccine, the safety committee of EMA is analyzing data provided by AstraZeneca on cases of Guillain-Barre syndrome (GBS). However, it did not specify the number of cases.</p> <p>The regulator said GBS was identified as a possible adverse event that needed to be specifically monitored during the vaccine&rsquo;s conditional approval process, adding it had requested more detailed data on the cases from AstraZeneca.</p> <p>However, researchers have ...</p><p><a href=https://www.benzinga.com/general/biotech/21/05/21016760/ema-safety-committee-reviews-heart-inflammation-rare-nerve-disorder-reports-after-pfizer-astrazen alt=EMA Safety Committee Reviews Heart Inflammation, Rare Nerve Disorder Reports After Pfizer, AstraZeneca COVID-19 Shots>Full story available on Benzinga.com</a></p> AZN Biotech BNTX COVID-19 Vaccine European Medicines Agency (EMA) Government JNJ MRNA News PFE Health Care FDA General AZN US0463531089 JNJ US4781601046 PFE US7170811035 MRNA US56804Q1022 BNTX News Biotech Government Health Care FDA General Benzinga Fri, 07 May 2021 19:56:10 +0000 Vandana Singh 21016760 at https://www.benzinga.com New SEC Chairman Gary Gensler Confirms A Lot Of Cryptocurrencies 'Are Indeed Securities,' Paving The Way For New Legislation https://www.benzinga.com/markets/cryptocurrency/21/05/21014629/new-sec-chairman-gary-gensler-confirms-a-lot-of-cryptocurrencies-are-indeed-securities-pav <p>Gary Gensler, the new chairman of the Securities and Exchange Commission, believes that more regulation is required in crypto markets.</p> <p><strong>What Happened: </strong>In an interview with <a href="https://www.cnbc.com/2021/05/07/sec-chairman-gary-gensler-says-more-investor-protections-are-needed-for-bitcoin-and-crypto-markets.html" style="color:#0563c1; text-decoration:underline">CNBC</a> on Friday, Gensler said that &ldquo;greater investor protection&rdquo; in the realm of cryptocurrencies was the need of the hour.</p> <p>&ldquo;To the extent that something is a security, the SEC has a lot of authority. And a lot of crypto tokens &mdash; I won&rsquo;t call them cryptocurrencies for this moment &mdash; are indeed securities,&rdquo; he said.</p> <p>Drawing attention to the enforcement actions brought ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/21/05/21014629/new-sec-chairman-gary-gensler-confirms-a-lot-of-cryptocurrencies-are-indeed-securities-pav alt=New SEC Chairman Gary Gensler Confirms A Lot Of Cryptocurrencies &#039;Are Indeed Securities,&#039; Paving The Way For New Legislation>Full story available on Benzinga.com</a></p> $BTC CNBC cryptocurrencies Cryptocurrency Fintech Gary Gensler Government News Legal SEC Markets $BTC News Government Cryptocurrency Fintech Legal SEC Markets Benzinga Fri, 07 May 2021 18:18:59 +0000 Samyuktha Sriram 21014629 at https://www.benzinga.com Crypto Mining Might Be In Danger In The State Of New York With This New Bill https://www.benzinga.com/markets/cryptocurrency/21/05/20960158/crypto-mining-might-be-in-danger-in-the-state-of-new-york-with-this-new-bill <p>A bill proposed in the New York State could force local miners of <strong>Bitcoin</strong> (CRYPTO: BTC) and other crypto assets to move or stop their activities for three years.</p> <p><strong>What Happened:</strong>&nbsp;<a href="https://legislation.nysenate.gov/pdf/bills/2021/S6486" rel="noopener nofollow" target="_blank">The New York Senate Bill</a>&nbsp;6486 was proposed by a Democrat&nbsp;senator and Chairman of Committee on Energy and Telecommunications, Kevin S. Parker.&nbsp;</p> <p>It was co-sponsored by the Chair of Committee on Aging, Chair of Legislative Commission on Rural Resources and&nbsp;Democrat senator Rachel May.</p> <p>The bill is aimed to enforce ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/21/05/20960158/crypto-mining-might-be-in-danger-in-the-state-of-new-york-with-this-new-bill alt=Crypto Mining Might Be In Danger In The State Of New York With This New Bill>Full story available on Benzinga.com</a></p> $BTC Bitcoin crypto mining cryptocurrencies Cryptocurrency environment Fintech Government new york News Regulations Legal Markets General $BTC News Government Cryptocurrency Regulations Fintech Legal Markets General Benzinga Fri, 07 May 2021 17:40:25 +0000 Adrian Zmudzinski 20960158 at https://www.benzinga.com Colorado Gov. Inks Bill To Expand Students' Access To Medical Marijuana, Could Raise Limit For Possession Next https://www.benzinga.com/markets/cannabis/21/05/20994138/colorado-gov-inks-bill-to-expand-students-access-to-medical-marijuana-could-raise-limit-for-poss <p>Colorado Gov. Jared Polis signed a bill on Wednesday that would expand&nbsp;access to medical cannabis for school children in need by removing obstacles to its administration.</p> <p>The new legislation, SB 21-056, removes the discretion from school principals to set policies that regulate storing and administering cannabis-based medicines.</p> <p>The bill&nbsp;places the responsibility on principals to &ldquo;create a written treatment plan for the administration of cannabis-based medicine and on school boards to adopt policies regarding actual administration.&rdquo;</p> <p>School boards will be called upon to create guidelines on how cannabis medicines should be stored.</p> <p>Governing bodies are also required to set rules that will allow personnel to voluntarily possess and administer medicinal cannabis to qualifying students.</p> <p>Gov. Polis said the measure was long overdue and called ...</p><p><a href=https://www.benzinga.com/markets/cannabis/21/05/20994138/colorado-gov-inks-bill-to-expand-students-access-to-medical-marijuana-could-raise-limit-for-poss alt=Colorado Gov. Inks Bill To Expand Students&#039; Access To Medical Marijuana, Could Raise Limit For Possession Next>Full story available on Benzinga.com</a></p> bill Cannabis Government Jared Polis News Regulations Politics Markets Media General News Government Cannabis Regulations Politics Markets Media General Benzinga Thu, 06 May 2021 19:00:46 +0000 Jelena Martinovic 20994138 at https://www.benzinga.com The Daily Dash: No More Money For PPP https://www.benzinga.com/government/21/05/20987726/the-daily-dash-no-more-money-for-ppp <p>The Daily Dash is a quick look at what&#039;s happening in the freight ecosystem. In today&#039;s edition, we highlight the latest news regarding the Paycheck Protection Program, interesting comments regarding the U.S.-Mexico border and more.</p> <h3 id="h-the-high-five">The High Five</h3> <p><strong>1. The Paycheck Protection Program has run out of money. </strong>With a May 31 deadline still a few weeks away — a date that is now mostly meaningless — the Small Business Administration confirmed reports that lenders who went online to submit new PPP applications were being rejected. <a href="https://www.freightwaves.com/news/ppps-2021-funds-exhausted-transportation-got-bigger-share-this-year"><strong><em>John Kingston&#039;s report</em></strong></a></p> <hr /> <p><strong>2. "I think we&#039;re going to see in the post-COVID-19 world </strong>a consolidation of supply chains that emphasize ‘hemispheric ...</p><p><a href=https://www.benzinga.com/government/21/05/20987726/the-daily-dash-no-more-money-for-ppp alt=The Daily Dash: No More Money For PPP>Full story available on Benzinga.com</a></p> Freight Freightwaves Government News ppp loans Regulations trucking Markets General News Government Regulations Markets General Benzinga Thu, 06 May 2021 14:55:44 +0000 FreightWaves 20987726 at https://www.benzinga.com Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move https://www.benzinga.com/general/biotech/21/05/20982778/biden-administration-backs-waiving-ip-protections-for-covid-19-vaccines-pharma-industry-rebukes-m <ul> <li>The closely watched issue of patent rights for COVID-19 vaccines garnered headlines again as the Biden administration came out in favor of a proposal at the World Trade Organization to suspend intellectual property protections for shots.</li> <li>U.S. Trade Representative Katherine Tai announced that the&nbsp;<a class="editor-rtfLink" href="https://twitter.com/AmbassadorTai/status/1390021205974003720" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Biden administration supports waiving IP protections</a>&nbsp;for COVID-19 vaccines. &ldquo;This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures,&rdquo; Tai said in the statement.</li> <li>Tai said the U.S. would actively participate in World Trade Organization text-based negotiations to make the waiver happen. She added that such discussions would take time, given the complexity of the issue involved.</li> <li>Tai also added that with the U.S. vaccine supply secured, the ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/20982778/biden-administration-backs-waiving-ip-protections-for-covid-19-vaccines-pharma-industry-rebukes-m alt=Biden Administration Backs Waiving IP Protections For COVID-19 Vaccines, Pharma Industry Rebukes Move>Full story available on Benzinga.com</a></p> AZN Biotech BNTX Briefs COVID-19 Vaccine Government GSK JNJ MRNA News NVX PFE Regulations Health Care FDA General NVX US67069X1046 AZN US0463531089 GSK US37733W1053 JNJ US4781601046 PFE US7170811035 MRNA US56804Q1022 BNTX News Biotech Government Regulations Health Care FDA General Benzinga Thu, 06 May 2021 11:20:03 +0000 Vandana Singh 20982778 at https://www.benzinga.com Eli Lilly Under FDA Scrutiny At Its COVID-19 Drug Manufacturing Facilities Amid Staff Accusations: Reuters https://www.benzinga.com/general/biotech/21/05/20966366/eli-lilly-under-fda-scrutiny-at-its-covid-19-drug-manufacturing-facilities-amid-staff-accusations <ul> <li><strong>Eli Lilly &amp; Co</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/lly#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">LLY</a>)&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/business/healthcare-pharmaceuticals/exclusive-lilly-hit-by-staff-accusations-fda-scrutiny-covid-drug-factories-2021-05-05/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">employees have reportedly accused a factory executive of altering documents</a>&nbsp;required by the FDA to downplay quality control problems at Branchburg, New Jersey plant producing its COVID-19 treatment.</li> <li>Reuters notes that an unsigned report was filed last month, which claims that the executive rewrote findings by Lilly&rsquo;s technical experts to make the conclusions appear more favorable to the company.</li> <li>The findings involved the production of drugs, including ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/20966366/eli-lilly-under-fda-scrutiny-at-its-covid-19-drug-manufacturing-facilities-amid-staff-accusations alt=Eli Lilly Under FDA Scrutiny At Its COVID-19 Drug Manufacturing Facilities Amid Staff Accusations: Reuters>Full story available on Benzinga.com</a></p> Biotech Briefs Government LLY News Reuters Health Care FDA General LLY US5324571083 News Biotech Government Health Care FDA General Benzinga Wed, 05 May 2021 18:08:34 +0000 Vandana Singh 20966366 at https://www.benzinga.com Why Shares Of Uber, Lyft And DoorDash Are Trading Lower Today https://www.benzinga.com/government/21/05/20966033/why-shares-of-uber-lyft-and-doordash-are-trading-lower-today <p>Uber (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>), Lyft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) and DoorDash (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dash#NYSE">DASH</a>) shares are trading lower on reports the Biden administration is planning to block a Trump-era rule that would have made it easier to classify gig workers ...</p><p><a href=https://www.benzinga.com/government/21/05/20966033/why-shares-of-uber-lyft-and-doordash-are-trading-lower-today alt=Why Shares Of Uber, Lyft And DoorDash Are Trading Lower Today>Full story available on Benzinga.com</a></p> DASH Government LYFT Regulations UBER why it's moving Movers Trading Ideas UBER LYFT DASH Government Regulations Movers Trading Ideas Benzinga Wed, 05 May 2021 14:20:59 +0000 Bill Haddad 20966033 at https://www.benzinga.com Lyft, GM Earnings Impress, Lifting Shares Ahead Of Uber's Report Slated For Later https://www.benzinga.com/news/earnings/21/05/20965987/lyft-gm-earnings-impress-lifting-shares-ahead-of-ubers-report-slated-for-later <p>If you wanted more evidence of reopening progress,&nbsp;<strong>Lyft&rsquo;s</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) earnings arguably provided it yesterday.</p> <p>The ride-sharing company saw shares post big pre-market gains after reporting a narrower than expected loss, above consensus revenue and solid guidance for the rest of the year. Now&nbsp;<strong>Uber</strong>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uber#NYSE">UBER</a>), which reports this afternoon, has a tough act to follow. Shares of LYFT spiked more than 5% in pre-market trading.&nbsp;</p> <p>&ldquo;More people started moving again&rdquo; in Q1, LYFT&rsquo;s chief financial officer said, which is the kind of thing you want to hear if you&rsquo;re excited about getting back to normal. Average daily ride volume grew each month, Lyft said, with the steepest recovery in March. And for people who miss traveling by plane, the good news is that LYFT&rsquo;s average daily airport rides were up more than 65% in April relative to January.&nbsp;</p> <p>What&rsquo;s more impressive is that all this happened even when most people weren&rsquo;t back at work yet. More companies are starting to talk about getting employees back to the office, so that could give ride-sharing companies an opportunity to do even better.&nbsp;</p> <p>Then this morning,&nbsp;<strong>General Motors&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gm#NYSE">GM</a>) easily beat Wall Street&rsquo;s earnings expectations but came up just short of consensus on revenue. It looks like investors aren&rsquo;t punishing the company for that small miss, as shares rose more than 3% in the pre-market hours. Maybe the fact that GM reaffirmed its 2021 guidance was enough to soothe any hurt feelings over revenue.</p> <p>The reaffirmed guidance from GM included an impact from the global shortage of semiconductor chips, by the way, so it doesn&rsquo;t look like that&rsquo;s going to necessarily handicap the company. This was an important thing for them to get across.&nbsp;</p> <p>The solid earnings from these two appeared to help stabilize a market that was going downhill yesterday. Major indices built in slight gains ahead of the opening bell. Earnings drive stocks, and the nice run of earnings continues.</p> <p>Forward progress early today might also reflect a bit of spillover buying after yesterday&rsquo;s late comeback from the lowest points of the day, but it&rsquo;s unclear how much buying interest remains with stocks still near record highs. It looks like we may bounce around in a range for a while as we get ready for the jobs report on Friday (see more below). There&rsquo;s also ISM Services data later today.</p> <h2>Not Like Old Times: Yellen Rate Hike Talk Spooks Stocks</h2> <p>Maybe you remember that time when, as Fed Chair, Janet Yellen gave Wall Street a scare by talking about how rates might need to rise to make sure the economy doesn&rsquo;t overheat.&nbsp;</p> <p>If you don&rsquo;t, it&rsquo;s understandable, because it&rsquo;s hard to remember many occasions when Yellen&mdash;&nbsp; a well-known dove&mdash;did that back in the day. While Yellen did raise rates slowly over the course of her time at the Fed, she did it very cautiously and without fireworks. Also, the economy really wasn&rsquo;t in much danger then of overheating, with slow growth being the big problem. That&rsquo;s why it might have felt a bit disconcerting to hear those words from her as Treasury Secretary yesterday, and helps explain the market&rsquo;s subsequent dive.</p> <p>It wouldn&rsquo;t be fair, however, to just blame Yellen. First of all, she didn&rsquo;t specifically call for a rate hike. She just said rates might have to rise to avoid the economy overheating, implying more of a natural progression considering the strong growth we&rsquo;ve seen so far this year. Already, many analysts see the 10-year yield on a path back toward 2%, though that&rsquo;s separate from the Fed raising rates.&nbsp;</p> <p>Yellen also walked back her words later Tuesday, according to The Wall Street Journal, saying she wasn&rsquo;t predicting nor recommending that the Federal Reserve raise interest rates, and doesn&rsquo;t think there&rsquo;s going to be an inflation problem.&nbsp;</p> <p>Second, the market was on its heels even before Yellen spoke. Almost none of the big Tech companies got a lift last week despite overwhelmingly impressive earnings results, and some &ldquo;mega-cap&rdquo; Tech stocks like&nbsp;<strong>Apple</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) and&nbsp;<strong>Tesla</strong>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) still haven&rsquo;t made it back to their February highs even ...</p><p><a href=https://www.benzinga.com/news/earnings/21/05/20965987/lyft-gm-earnings-impress-lifting-shares-ahead-of-ubers-report-slated-for-later alt=Lyft, GM Earnings Impress, Lifting Shares Ahead Of Uber&#039;s Report Slated For Later>Full story available on Benzinga.com</a></p> AAPL AVGO Earnings GM Government Lyft LYFT MRK News NVDA PFE Regulations TDAmeritrade tech stocks TSLA Uber UBER FDA Markets Tech Media General AAPL US0378331005 NVDA US67066G1040 GM US37045V1008 MRK US58933Y1055 PFE US7170811035 AVGO SG9999006241 TSLA US88160R1014 UBER LYFT News Earnings Government Regulations FDA Markets Tech Media General Benzinga Wed, 05 May 2021 14:19:46 +0000 JJ Kinahan 20965987 at https://www.benzinga.com Europe To Get Novavax COVID-19 Vaccines But Not Before End Of 2021: Reuters https://www.benzinga.com/general/biotech/21/05/20920472/europe-to-get-novavax-covid-19-vaccines-but-not-before-end-of-2021-reuters <ul> <li><strong>Novavax Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/nvax#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">NVAX</a>) has told the European Union it&nbsp;<a class="editor-rtfLink" href="https://www.reuters.com/world/europe/exclusive-novavax-plans-ship-covid-19-vaccines-europe-late-2021-eu-source-2021-05-03/" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">plans to begin delivering its COVID-19 vaccine</a>&nbsp;to the bloc towards the end of this year,</li> <li>A formal contract could be signed as early as this week, an E.U. official told Reuters.</li> <li>A deal would see Novavax supply a total of up to 200 million doses of the vaccine, providing the E.U. with booster shots to help contain the coronavirus and potentially guard against new variants.</li> <li>Novavax reached a preliminary deal with the union in December, but a final agreement ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/20920472/europe-to-get-novavax-covid-19-vaccines-but-not-before-end-of-2021-reuters alt=Europe To Get Novavax COVID-19 Vaccines But Not Before End Of 2021: Reuters>Full story available on Benzinga.com</a></p> Biotech BNTX Briefs COVID-19 Vaccine Government News NVAX PFE Reuters Health Care Contracts General NVAX US6700021040 PFE US7170811035 BNTX News Biotech Government Health Care Contracts General Benzinga Mon, 03 May 2021 18:52:40 +0000 Vandana Singh 20920472 at https://www.benzinga.com Enviromental Due Diligence In The Cannabis Industry: Why A Phase I Is The Best Money You Can Spend https://www.benzinga.com/markets/cannabis/21/05/20775114/enviromental-due-diligence-in-the-cannabis-industry-why-a-phase-i-is-the-best-money-you-can-spen <p><strong><em>By Doug Brown, ASTI Environmental.</em></strong></p> <p>So you&rsquo;re looking at buying property to build a grow facility or a dispensary, perhaps it&rsquo;s your first foray into real estate, you hear the word Brownfield, and your attorney or colleague tells you to get a Phase I...&nbsp;Now what?</p> <p>Engaging an Environmental Professional to conduct a Phase I Environmental Site Assessment (Phase I) is the first step to obtain liability protection both federally and with the State should the property you intend to purchase have recognized environmental conditions (RECs).&nbsp; An ASTM E1527-13 Phase I is the only environmental screening product that affords liability protection and includes:</p> <ul> <li> <p>A review of prior environmental reports (if available)</p> </li> <li> <p>Freedom of Information Act (FOIA) requests are submitted to the State and the Municipality where the property is located</p> </li> <li> <p>The purchase of an environmental database</p> </li> <li> <p>An Environmental questionnaire being sent to the buyer and seller</p> </li> <li> <p>Aerial and Sanborn Map review</p> </li> <li> <p>Site reconnaissance&nbsp;&nbsp;</p> </li> </ul> <p>We publish a 600-700 page report and a key paragraph confirms whether or not there are RECs. If RECs are not identified in the Phase I, then the Phase I report would be finalized and the process would be complete.&nbsp;</p> <p><strong>OK, so what&rsquo;s a REC ??</strong></p> <p>The presence, or likely presence, of hazardous substances or petroleum products on a property under conditions that indicate an existing release, a past release, or the material threat of a release into ...</p><p><a href=https://www.benzinga.com/markets/cannabis/21/05/20775114/enviromental-due-diligence-in-the-cannabis-industry-why-a-phase-i-is-the-best-money-you-can-spen alt=Enviromental Due Diligence In The Cannabis Industry: Why A Phase I Is The Best Money You Can Spend>Full story available on Benzinga.com</a></p> Cannabis Cannabis Dispensaries Government Phase I Regulations Small Business Markets Government Cannabis Regulations Small Business Markets Benzinga Mon, 03 May 2021 15:00:24 +0000 Benzinga Cannabis Contributors 20775114 at https://www.benzinga.com Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4 https://www.benzinga.com/general/biotech/21/05/20910939/moderna-inks-supply-pact-of-500m-covid-19-vaccine-doses-to-covax-effort-starting-q4 <ul> <li><strong>Moderna Inc</strong>&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mrna#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">MRNA</a>) has announced an agreement with vaccine promoter Gavi&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/05/b20909662/moderna-announces-supply-agreement-with-gavi-for-up-to-500-million-doses-of-covid-19-vaccine-moder" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">to supply up to 500 million doses</a>&nbsp;of its COVID-19 vaccine to boost the global vaccination effort. Still, most of the shipments won&rsquo;t arrive until next year.</li> <li>Initially, 34 million doses will be delivered in the fourth quarter of 2021.</li> <li>The company will supply as ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/05/20910939/moderna-inks-supply-pact-of-500m-covid-19-vaccine-doses-to-covax-effort-starting-q4 alt=Moderna Inks Supply Pact Of 500M COVID-19 Vaccine Doses To COVAX Effort Starting Q4>Full story available on Benzinga.com</a></p> AZN Biotech BNTX Briefs COVID-19 Vaccine Government MRNA News PFE Health Care Contracts General AZN US0463531089 PFE US7170811035 MRNA US56804Q1022 BNTX News Biotech Government Health Care Contracts General Benzinga Mon, 03 May 2021 10:49:55 +0000 Vandana Singh 20910939 at https://www.benzinga.com Tesla Said To Be Beefing Up Government Relations Team In China Amid Intense Regulatory Scrutiny https://www.benzinga.com/government/21/05/20909207/tesla-said-to-be-beefing-up-government-relations-team-in-china-amid-intense-regulatory-scrutiny <p><strong>Tesla Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) is stepping up engagement with regulators and strengthening its government relations team in China where it is facing scrutiny over safety and customer service complaints, Reuters <a href="https://www.reuters.com/world/china/exclusive-tesla-under-scrutiny-china-steps-up-engagement-with-regulators-sources-2021-05-03/" style="text-decoration:none">reported</a> on Monday &mdash; citing industry sources.</p> <p><strong>What Happened: </strong>Tesla executives have, in recent weeks, participated in four policy discussions on topics ranging from auto data storage, vehicle-to-infrastructure communication technologies, car recycling and carbon emissions, according to the Reuters report.</p> <p>The California-based company is reportedly&nbsp;yet to make any firm commitments.</p> <p><em>See Also: <a href="https://www.benzinga.com/news/21/04/20762349/will-tesla-shanghai-auto-show-incident-be-a-watershed-event-for-rise-of-local-rivals-like-nio-xpeng" style="text-decoration:none">Will Tesla Shanghai Auto Show Incident Be A &#39;Watershed Event&#39; For Rise Of Local Rivals Like Nio, Xpeng?</a></em></p> <p>Tesla is&nbsp;also ramping ...</p><p><a href=https://www.benzinga.com/government/21/05/20909207/tesla-said-to-be-beefing-up-government-relations-team-in-china-amid-intense-regulatory-scrutiny alt=Tesla Said To Be Beefing Up Government Relations Team In China Amid Intense Regulatory Scrutiny>Full story available on Benzinga.com</a></p> China electric vehicles Elon Musk EVs Government News Regulations TSLA Global Tech TSLA US88160R1014 News Government Regulations Global Tech Benzinga Mon, 03 May 2021 08:57:02 +0000 Rachit Vats 20909207 at https://www.benzinga.com Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg https://www.benzinga.com/general/biotech/21/04/20893931/emergent-biosolutions-has-supply-of-60m-johnson-johnson-covid-19-vaccine-doses-awaiting-approval- <ul> <li><strong>Emergent BioSolutions Inc&nbsp;</strong>(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ebs#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">EBS</a>) has manufactured over 115 million doses of drug substance used in the&nbsp;<strong>Johnson &amp; Johnson</strong>&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/jnj#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">JNJ</a>) COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at U.S. regulators&rsquo; discretion,&nbsp;<a class="editor-rtfLink" href="https://www.bloomberg.com/news/articles/2021-04-29/tens-of-millions-of-j-j-doses-sit-on-shelves-awaiting-fda-review?sref=TBDibEcD" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">reports Bloomberg</a>.</li> <li>The contract manufacturer has been producing the J&amp;J single-shot vaccine since late 2020, according to a source.</li> <li>The stockpile size, which is not yet cleared by the FDA for release, hasn&rsquo;t been previously reported.</li> <li>A Biden administration official did confirm the numbers but declined ...</li></ul><p><a href=https://www.benzinga.com/general/biotech/21/04/20893931/emergent-biosolutions-has-supply-of-60m-johnson-johnson-covid-19-vaccine-doses-awaiting-approval- alt=Emergent BioSolutions Has Supply Of 60M Johnson &amp; Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg>Full story available on Benzinga.com</a></p> AZN Biotech Bloomberg Briefs EBS Government JNJ News Health Care Contracts FDA General AZN US0463531089 EBS US29089Q1058 JNJ US4781601046 News Biotech Government Health Care Contracts FDA General Benzinga Fri, 30 Apr 2021 18:35:54 +0000 Vandana Singh 20893931 at https://www.benzinga.com